vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues

vTv Therapeutics Inc.

Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.
Cash $41.6M at Sep 30, 2024, up from $9.4M at Dec 31, 2023, boosted by private placement and ATM.
R&D spend $3.2M (up from $2.8M) on higher indirect costs; G&A $3.3M (up from $2.5M) due to share-based and legal.
Cadisegliatin program under FDA clinical hold since July 2024; company addressing basis for hold.
No revenue in Q3 2024; YTD revenue $1.0M from prior periods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.